This is a working overview of tuftsin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
=== Reducing end === Disaccharides consist of two monosaccharides and may be either reducing or nonreducing. Even a reducing disaccharide will only have one reducing end, as disaccharides are held together by glycosidic bonds, which consist of at least one anomeric carbon. With one anomeric carbon unable to convert to the open-chain form, only the free anomeric carbon is available to reduce another compound, and it is called the reducing end of the disaccharide. A nonreducing disaccharide is that which has both anomeric carbons tied up in the glycosidic bond. Similarly, most polysaccharides have only one reducing end.
=== Political donations (2018) === In 2018, In-N-Out faced calls for boycott after donating $25,000 to the California GOP ahead of the November elections, as well as $30,000 in August 2017 and another $30,000 in May 2016.
== Comparative evolutionary studies == Comparative genomic analyses of the Notch receptor family across mammals have begun to reveal how evolutionary conservation and lineage-specific variation contribute to receptor function and disease susceptibility. Large-scale studies of NOTCH3 across more than 100 mammalian species have identified a high degree of structural conservation, particularly within the extracellular EGF-like repeats that are critical for ligand binding and receptor stability. These analyses have also uncovered rare, naturally occurring species-specific variations, including alterations in conserved cysteine residues and regulatory regions, that appear to be tolerated in some mammals but are pathogenic in humans. Such findings suggest that evolutionary divergence within Notch receptors can illuminate structural constraints and functional thresholds that are not easily detected in single-species studies. Experimental introduction of naturally occurring mammalian variants into model systems has been proposed as a strategy to test bioinformatic predictions and to better understand how subtle changes in Notch receptor structure influence signaling, development, and disease.
hydrogenation Any chemical reaction between molecular hydrogen (H2) and another chemical species, typically resulting in the reduction or saturation of the other species by the addition of one or more pairs of hydrogen atoms to a compound or element. The presence of a catalyst is usually required for hydrogenation reactions to occur; non-catalytic hydrogenation takes place only at extreme temperatures.
Sources: en.wikipedia.org
In group 14, both metallic and covalent bonding become possible. In a diamond crystal, covalent bonds between carbon atoms are strong, because they have a small atomic radius and thus the nucleus has more of a hold on the electrons. Therefore, the bonding orbitals that result are much lower in energy than the antibonding orbitals, and there is no overlap, so electrical conduction becomes impossible: carbon is a nonmetal. However, covalent bonding becomes weaker for larger atoms and the energy gap between the bonding and antibonding orbitals decreases. Therefore, silicon and germanium have smaller band gaps and are semiconductors at ambient conditions: electrons can cross the gap when thermally excited. (Boron is also a semiconductor at ambient conditions.) The band gap disappears in tin, so that tin and lead become metals. As the temperature rises, all nonmetals develop some semiconducting properties, to a greater or lesser extent depending on the size of the band gap. Thus metals and nonmetals may be distinguished by the temperature dependence of their electrical conductivity: a metal's conductivity lowers as temperature rises (because thermal motion makes it more difficult for the electrons to flow freely), whereas a nonmetal's conductivity rises (as more electrons may be excited to cross the gap). Elements in groups 15 through 17 have too many electrons to form giant covalent molecules that stretch in all three dimensions.
Several naturally-preserved, unintentional mummies dating from the Incan period (1438–1532 AD) have been found in the colder regions of Argentina, Chile, and Peru. These are collectively known as "ice mummies". The first Incan ice mummy was discovered in 1954 atop El Plomo Peak in Chile, after an eruption of the nearby volcano Sabancaya melted away ice that covered the body. The Mummy of El Plomo was a male child who was presumed to be wealthy due to his well-fed bodily characteristics. He was considered to be the most well-preserved ice mummy in the world until the discovery of Mummy Juanita in 1995. Mummy Juanita was discovered near the summit of Ampato in the Peruvian section of the Andes mountains by archaeologist Johan Reinhard. Her body had been so thoroughly frozen that it had not been desiccated; much of her skin, muscle tissue, and internal organs retained their original structure. She is believed to be a ritual sacrifice, due to the close proximity of her body to the Incan capital of Cusco, as well as the fact she was wearing highly intricate clothing to indicate her special social status. Several Incan ceremonial artifacts and temporary shelters uncovered in the surrounding area seem to support this theory. More evidence that the Inca left sacrificial victims to die in the elements, and later be unintentionally preserved, came in 1999 with the discovery of the Llullaillaco mummies on the border of Argentina and Chile. The three mummies are children, two girls and one boy, who are thought to be sacrifices associated with the ancient ritual of qhapaq hucha.
Dried fruit Soft drinks Juice Sugar as sweets, tablets or cubes. The anti-hypertensive class of medication known as calcium channel blockers could be useful for reactive hypoglycemia as inhibition of the calcium channels on beta islet cells can help prevent an overproduction of insulin after a meal is eaten.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.